Exelixis, Inc. (ticker: EXEL, exchange: NASDAQ Global Market (.O))
News Release -
Exelixis Announces Date of 2004 Annual Meeting of Stockholders
SOUTH SAN FRANCISCO, Calif., Jan. 15 /PRNewswire-FirstCall/ -- Exelixis,
Inc. (Nasdaq: EXEL) announced that it intends to hold its 2004 annual meeting
of stockholders on April 8, 2004 at 8:00 a.m. PDT at the company's offices
located at 170 Harbor Way, South San Francisco, California 94080.
The deadline for submission of stockholder proposals that are not intended
to be included in the company's proxy materials is Friday, February 6, 2004.
Exelixis, Inc. is a leading genomics-based drug discovery company
dedicated to the discovery and development of novel therapeutics. The company
is leveraging its fully integrated gene-to-drug platform to fuel the growth of
its proprietary drug pipeline. Exelixis' development pipeline includes: XL119
which is anticipated to enter a Phase 3 clinical trial as a potential
treatment for bile duct tumors; XL784, an anticancer compound that has
completed a Phase 1 clinical trial; XL647, XL999 and XL844, anticancer
compounds that are potential IND candidates; and multiple compounds in
preclinical development. Exelixis has established broad corporate alliances
with major pharmaceutical and biotechnology companies, including
GlaxoSmithKline and Bristol-Myers Squibb Company. The company has also
established agricultural research collaborations with Bayer CropScience, Dow
AgroSciences and Renessen LLC. Other partners include Merck & Co., Inc.,
Schering-Plough Research Institute, Inc., Cytokinetics, Inc., Elan
Pharmaceuticals, Inc. and Scios Inc. For more information, please visit the
company's web site at www.exelixis.com.
This press release contains forward-looking statements, including
statements related to plans to commence a phase 3 clinical trial of XL119.
Words such as "believes," "anticipates," "plans," "expects," "intend," "will"
and similar expressions are intended to identify forward-looking statements.
These forward-looking statements are based upon Exelixis' current
expectations. Forward-looking statements involve risks and uncertainties.
Exelixis' actual results and the timing of events could differ materially from
those anticipated in such forward-looking statements as a result of these
risks and uncertainties, which include, without limitation, the risk factors
discussed under "Risk Factors" and elsewhere in our quarterly report on Form
10-Q for the quarter ended September 30, 2003 and other filings with the
Securities and Exchange Commission. The company expressly disclaims any
obligation or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change in our
expectations with regard thereto or any change in events, conditions or
circumstances on which any such statements are based.
Exelixis and the Exelixis logo are registered U.S. trademarks.
Spectrum selective kinase inhibitor is a trademark of Exelixis, Inc.
SOURCE Exelixis, Inc.
/CONTACT: Jane M. Green, Ph.D., VP, Corporate Communications, of
Exelixis, Inc., +1-650-837-7579 or firstname.lastname@example.org/
/Web site: http://www.exelixis.com /
CO: Exelixis, Inc.
IN: HEA MTC
-- SFTH065 --
2518 01/15/2004 16:00 EST http://www.prnewswire.com